Back to Research

Organization profile

WAMA Diagnostics

(Confidence level: high) WAMA Diagnostics is an international leader in laboratory diagnostics, founded in 1991 in Brazil and expanded to Switzerland in 2015. The organization focuses on the research, development, and production of in vitro diagnostic (IVD) kits and reagents, particularly specializing in immunodiagnostics, lateral flow technology, and urine analysis.38

Monthey, SwitzerlandFounded 2016

Overview

1. Executive Summary (Confidence: High)

WAMA Diagnostics is characterized by a "rigorous quality control" philosophy and a mission to lead the global diagnostics market through innovation. The company’s Brazilian headquarters manages a vast production line of reagents and equipment, certified by ANVISA (GMP) and BSI (ISO 13485). Its Swiss subsidiary, WAMA Diagnostics Switzerland, serves as a specialized R&D hub in Monthey, where it has developed SafeBlood, a groundbreaking multiplex immunoassay for blood bank screening. SafeBlood can detect six transfusion-transmissible pathogens (including HIV, Syphilis, and Hepatitis) in a single reaction well using only 20µL of sample. With clinical sensitivity benchmarks exceeding 96.15% and support from European financing programs like Eurostars, WAMA is positioned to significantly disrupt the European blood screening market by reducing laboratory costs by up to 50%.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.